Amphix Bio
Health Care
$22.8Mtotal raised · 4 rounds on record
$12.5Mlatest round · Seed · Dec 2025 · 10 mo ago
$1.3Mgrants · 2 grants · CORDIS
10+team · employees, estimated range
Overview
Amphix Bio is a preclinical stage company developing a new platform technology, Supramolecular Therapeutic Peptides (STPs), that modifies immunological response and initiates regenerative processes to restore function lost from injury, disease, or aging.
Funding and backers
Total raised
$22.8M
4 rounds on record
Latest round
$12.5M
Seed · Dec 2025 · 10 mo ago
Team
11-50
employees, estimated range
Grants
$1.3M
2 grants · CORDIS
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 18, 2025
Raised a round Seed $12.5M · PRNewswire
Sep 15, 2024
Won a grant $1M · CORDIS
Mar 1, 2022
Won a grant $253k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Dec 2025 | $12.5M | — | PRNewswire |
| Venture round | Dec 2025 | $10.3M | — | SEC Form D |
| Grant | Sep 2024 | $1M | — | CORDIS |
| Grant | Mar 2022 | $253k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | Amphix Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Samuel StuppExecutive Officer, DirectorSEC Form D
Nicholas SatherExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Dimension Bio is a biotechnology company pioneering regenerative therapeutics. We design lifesaving solutions that restore organ function…
Restoring Nerve Function. Solaxa is a clinical-stage biopharmaceutical company developing life-altering solutions that reignite function…
Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome…
Bioptamers is a preclinical-stage biotech company developing personalized precision therapies for oncology patients.
Reprogrammable RNA therapies for regeneration and longevity.. RNARevive is a science-driven biotech developing reprogrammable RNA…
Refoxy Pharmaceuticals GmbH is a pre-clinical biotech company developing FOXO3-targeting therapies to restore cellular balance and treat…
People
Samuel Stupp
Executive Officer, Director
Nicholas Sather
Executive Officer, Director
Kok-Wai Wong
Director
Stephen Wilson
Director
John Potocsnak
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Post-stroke injection protects the brain in preclinical study
Nanomaterial crosses blood-brain barrier, targets harmful inflammation after most common type of stroke
Read more
Report
Amphix Bio: $12.5 Million Seed Funding Raised To Advance Peptide Therapeutics Toward Clinical Trials
Amphix Bio announced it has completed the initial closing of a $12.5 million seed financing round to move its lead therapeutic candidates toward human clinical trials and expand its pipeline into additional neurological conditions. The Chicago-based compa
Read more
Report
Amphix Bio raises $12.5M seed round to advance peptide drug platform
/PRNewswire/ -- Amphix Bio today announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human...
Read more
Report
FDA Grants Amphix Bio's AMFX-200 Orphan Drug Designation PharmExec
Amphix Bio leads breakthrough of regenerative spinal cord injury treatment.
Read more
Report
Amphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute spinal cord injury
CHICAGO, July 16, 2025 /PRNewswire/ --Amphix Bio, a pre-clinical stage company developing a new therapeutic modality for regenerative medicine, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate AMF
Read more
Report
Amphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute spinal cord injury
/PRNewswire/ -- Amphix Bio, a pre-clinical stage company developing a new therapeutic modality for regenerative medicine, received an Orphan Drug Designation...
Read more
Report
Amphix Bio lands federal and state grants to manufacture regenerative therapies
/PRNewswire/ -- Amphix Bio, a company developing a new class of regenerative medicine therapies, announced that it has secured a $1M Small Business Innovation...
Read more
Report
Amphix Bio obtains FDA breakthrough device status for bone regeneration product
The company's bone regeneration product is designed to transform spinal fusion surgeries.
Read more
Report
FDA grants Breakthrough Device designation to Amphix Bio
/PRNewswire/ -- Amphix Bio, a company developing a new class of regenerative medicine therapies, announced today it has received a Breakthrough Device...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chicago
United States
HQ
10-50 est. staff